C-reactive protein (CRP) at admission: is it really usefull in COVID-19 pneumonia?

B. Basina (Dnipro, Ukraine), K. Bielosludtseva (Dnipro, Ukraine), T. Pertseva (Dnipro, Ukraine), T. Kirieieva (Dnipro, Ukraine), M. Krykhtina (Dnipro, Ukraine), N. Kravchenko (Dnipro, Ukraine)

Source: Virtual Congress 2021 – COVID - 19 biomarkers
Session: COVID - 19 biomarkers
Session type: E-poster
Number: 654

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. Basina (Dnipro, Ukraine), K. Bielosludtseva (Dnipro, Ukraine), T. Pertseva (Dnipro, Ukraine), T. Kirieieva (Dnipro, Ukraine), M. Krykhtina (Dnipro, Ukraine), N. Kravchenko (Dnipro, Ukraine). C-reactive protein (CRP) at admission: is it really usefull in COVID-19 pneumonia?. 654

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Diagnostic accuracy of lipopolysaccharide-binding protein (LBP), fibrinogen and C-reactive protein (CRP) in differentiating pneumonia from acute bronchitis in primary care
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007


Prognosis value of initial C-reactive protein (CRP) assay in patients with community acquired pneumonia
Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention
Year: 2008


C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP)
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016


C-reactive protein (CRP), an early prognostic tool in community acquired pneumonia (CAP)
Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia
Year: 2009


Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP)
Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment
Year: 2013


C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis
Source: Annual Congress 2012 - Infections and sepsis in the ICU
Year: 2012


Can Neutrophil/lymphocyte Ratio, C-reactive protein (CRP) and Procalcitonin predict the hospitalization time in patients with lower tract respiratory infections ?
Source: International Congress 2019 – Pleural infection and complicated pneumonia
Year: 2019

Is there a relationship between severity of COPD and C-reactive protein (CRP) levels?
Source: Eur Respir J 2006; 28: Suppl. 50, 37s
Year: 2006

Does the serum C-reactive protein (CRP) predict adverse outcomes in patients admitted with community acquired pneumonia?
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


D-dimer to C-reactive protein (CRP) ratio in patients with suspected pulmonary embolism
Source: Annual Congress 2010 - Pulmonary embolism
Year: 2010


Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia
Source: Eur Respir J 2005; 25: 688-692
Year: 2005



Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 488s
Year: 2006

C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 545s
Year: 2005

Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008


C-reactive protein (CRP) in the prognosis of complications of parapneumonic effusions (PPE)
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010


The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 241s
Year: 2004

C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study
Source: Eur Respir J 2005; 25: 804-812
Year: 2005



Levels of serum amyloid A (SAA) and C-reactive protein (CRP) in stable COPD patients and its relationship with disease severity.
Source: International Congress 2017 – COPD biomarkers
Year: 2017